Literature DB >> 817407

Current and proposed management of ocular herpes simplex.

J McGill, F T Fraunfelder, B R Jones.   

Abstract

Current and proposed methods of management of ocular herpetic epithelial disease are reviewed with particular attention to the methods, efficacy and side effects of mechanical debridement, chemotherapy, cryotherapy, and photoinactivation. Special types of herpetic ulceration, including steroid-induced, resistant, indolent, and recurrent ulcers are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 817407     DOI: 10.1016/s0039-6257(96)90004-1

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  6 in total

1.  Suppurative corneal ulceration following herpetic keratitis.

Authors:  K R Wilhelmus
Journal:  Doc Ophthalmol       Date:  1982-05-14       Impact factor: 2.379

2.  Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers.

Authors:  J McGill; P Tormey; C B Walker
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

3.  Treatment of experimental herpes simplex keratitis with acycloguanosine.

Authors:  D J Bauer; P Collins; W E Tucker; A W Macklin
Journal:  Br J Ophthalmol       Date:  1979-06       Impact factor: 4.638

4.  Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir.

Authors:  Ravi S Talluri; Swapan K Samanta; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-06-23       Impact factor: 5.875

5.  Pharmacokinetics of Stereoisomeric Dipeptide Prodrugs of Acyclovir Following Intravenous and Oral Administrations in Rats: A Study Involving In vivo Corneal Uptake of Acyclovir Following Oral Dosing.

Authors:  Ravi S Talluri; Ripal Gaudana; Sudharshan Hariharan; Ashim K Mitra
Journal:  Ophthalmol Eye Dis       Date:  2009-10-21

6.  Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections.

Authors:  Yuko Hara; Atsushi Shiraishi; Takeshi Kobayashi; Yuko Kadota; Yuji Shirakata; Koji Hashimoto; Yuichi Ohashi
Journal:  Mol Vis       Date:  2009-05-08       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.